Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals Stock Is Rising Today

By Prosper Junior Bakiny – Apr 23, 2020 at 1:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company continues to post staggering gains thanks to its efforts to develop a vaccine for COVID-19.

Shares of Inovio Pharmaceuticals (INO -7.47%) were up by 10.4% as of 12:41 p.m. EDT on Thursday. There was no company-specific news that drove the stock higher, but Inovio's shares have more than tripled since the beginning of the year due to its efforts to develop a vaccine for COVID-19. Today's gains are likely a continuation of that trend. 

So what?

Inovio has been racing through the early stages of the development of its potential COVID-19 vaccine, INO-4800. The company claimed that on Jan. 10, it created INO-4800 in three hours after Chinese researchers publicly released the genetic sequence of the SARS-CoV-2 virus that causes COVID-19. On April 6, Inovio started a phase 1 clinical trial for its investigational COVID-19 vaccine.

The trial will involve up to 40 healthy adult volunteers who will each receive two doses of the vaccine four weeks apart. The goals of the trial are to test the vaccine's safety and its ability to trigger an immune response in the body. Inovio expects data from this trial by late summer.

A note on a clipboard that says "coronavirus" with a check mark.

Image source: Getty Images.

Now what?

Investors are hopeful that Inovio will make a fortune off of its investigational COVID-19. However, the biotech company remains a risky bet. Inovio has no approved products on the market, and there's no guarantee that its potential vaccine for COVID-19 will ever earn regulatory approval, much less that it will be the only one to do so. In short, betting that Inovio's current efforts to develop a COVID-19 vaccine will pan out is, at this point, a long shot. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
INO
$1.61 (-7.47%) $0.13
Novavax Stock Quote
Novavax
NVAX
$16.30 (-9.85%) $-1.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
338%
 
S&P 500 Returns
108%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.